News Archive - Page 6 of 6 - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

News

LATEST UPDATES

READ MORE

Possible therapeutic targets found in comprehensive #genome study in small cell #lungcancer; research supported by SU2C

An international team of scientists have published a report that presents a comprehensive picture of the genetic alterations (or mutations) involved in small cell lung cancer (SCLC), a particularly deadly form of the disease. The research was supported in part by an Innovative Research Grant made by SU2C in 2009.

Read More
READ MORE

Scientists supported by SU2C have made important findings in advanced prostate cancer

The Wall Street Journal has reported on a paper from the SU2C-PCF Prostate Cancer Dream Team that was published in the prestigious journal Cell. The Cell paper reported that up to 90 percent of samples from patients with advanced prostate cancer harbored some kind of genetic anomaly that was clinically actionable, meaning we have potential treatments to target that specific aberration. The WSJ article focuses specifically on the presence of BRCA1 and BRCA2 genes, which may be treatable with drugs called PARP inhibitors.  Dr. Arul Chinnaiyan of the University of Michigan and Dr. Charles Sawyers of Memorial Sloan Kettering Cancer Center, co-leaders of the Dream Team, discuss the significance of the team’s findings in the Journal article, with comment from SU2C SAC Vice-Chair Dr. William Nelson, director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Read More
READ MORE

New class of drugs show anti-tumor activity, research supported by SU2C scientists

Forbes Contributor, Elaine Schattner, writes about several pieces of research that were presented at the recent Annual Meeting of the American Association for Cancer Research.  A physician herself, Schattner lays out the evidence that the drug olaparib has unexpected anti-tumor activity in ovarian and prostate cancers.  SU2C was proud to support the studies presented by Ursula Matulonis, MD, of Dana-Farber Cancer Institute and Joaquin Mateo, MD, of the Institute for Cancer Research in the U.K.

Read More
READ MORE

Scientists Supported by SU2C Build Cell Model to Study Colon Cancer

In research supported in part by Stand Up To Cancer, scientists in the Netherlands have created a model using living cells that will help researchers study the processes involved in the development of colon cancer.  The model will also help discover which drugs will work against cancerous cells. 

Developed in the laboratory of Hans Clevers, MD, PhD, professor at the Hubrecht Institute in Utrecht, the model utilizes organoids, which are made from cultured human tissues. SU2C and the Dutch Cancer Society launched a Dream Team headed by Clevers along with Johannes Bos, PhD, chairman of the department of molecular cancer research at University Medical Center Utrecht, to support the organoid work in November 2013. The SU2C Dream Team grants are administered by SU2C’s Scientific Partner, the American Association for Cancer Research (AACR).

Read More
READ MORE

UCLA Scientists Discover How Melanoma Resists Certain Treatment

Read More